Cryptococcal meningitis is a serious fungal infection of the membranes surrounding the brain and spinal cord. It’s caused by inhaling microscopic spores of a fungus called Cryptococcus, which first infects the lungs and then spreads through the bloodstream to the central nervous system. An estimated 152,000 cases occur each year among people living with HIV worldwide, making it one of the leading causes of death in that population.
How the Infection Develops
Cryptococcus fungi live in soil and the environment. The species responsible for most infections, Cryptococcus neoformans, is found worldwide. A second species, Cryptococcus gattii, tends to live in tropical and subtropical regions, though it has also been identified in cooler areas like British Columbia and parts of the Pacific Northwest.
You breathe in tiny fungal spores without realizing it. In most healthy people, the immune system clears the spores or keeps them contained in the lungs indefinitely. But in people with weakened immune systems, the fungus can grow unchecked. It first establishes a lung infection that can look like pneumonia, then enters the bloodstream and travels to the brain and spinal cord, where it causes inflammation known as meningoencephalitis.
This process can unfold over days to weeks, which is one key difference from bacterial meningitis, where symptoms often come on within hours. The slower, creeping onset of cryptococcal meningitis means it’s sometimes mistaken for other conditions before the correct diagnosis is made.
Who Is Most at Risk
HIV is by far the biggest risk factor. The vast majority of cryptococcal meningitis cases occur in people living with advanced HIV whose immune systems are severely suppressed, particularly when the CD4 cell count drops very low. Sub-Saharan Africa bears the heaviest burden, accounting for most of the estimated 112,000 deaths from the disease each year.
People without HIV can also develop cryptococcal meningitis if their immune systems are compromised by other conditions. Organ transplant recipients taking anti-rejection medications, people on long-term corticosteroids or other immunosuppressive drugs, and those with certain blood cancers or liver disease all face elevated risk. Rarely, people with no obvious immune problems develop the infection, particularly from C. gattii.
Symptoms to Recognize
The hallmark symptoms are headache, fever, and neck stiffness, similar to other forms of meningitis. But cryptococcal meningitis often develops more gradually, with symptoms building over one to two weeks rather than appearing suddenly.
As the infection progresses, it can cause confusion, personality changes, sensitivity to light, blurred or double vision, and nausea or vomiting. Some people experience seizures. One of the most dangerous effects is rising pressure inside the skull as the infection disrupts the normal flow of cerebrospinal fluid. If that pressure isn’t managed, it can cause severe neurological damage, vision loss, or death.
How It’s Diagnosed
Diagnosis relies on detecting the fungus or its chemical signature in blood or cerebrospinal fluid (the fluid surrounding the brain and spinal cord, collected through a spinal tap). The most widely used test looks for a protein shed by the fungus, called cryptococcal antigen. A rapid version of this test, the lateral flow assay, is highly accurate, with a sensitivity of 99.3% and specificity of 99.1%. That means it catches nearly every true case while producing very few false positives.
The spinal tap itself also provides critical information beyond diagnosis. Measuring the opening pressure of the cerebrospinal fluid tells doctors how much pressure has built up inside the skull, which directly guides treatment decisions.
Treatment: A Three-Phase Process
Treating cryptococcal meningitis is a long process divided into three phases, each with a different goal.
The first phase, called induction, lasts about two weeks and uses the most aggressive antifungal medications, typically delivered intravenously in a hospital. The aim is to kill as much of the fungus as quickly as possible. In settings where daily monitoring is available, this usually involves a combination of two powerful antifungal drugs given together. In resource-limited settings, a newer approach uses a single high-dose infusion on the first day followed by oral medications for the remaining two weeks.
The second phase, consolidation, shifts to oral antifungal medication at a high dose for at least eight weeks. During this time, doctors monitor whether the cerebrospinal fluid has cleared of the fungus. If it hasn’t, the treatment is intensified.
The third phase, maintenance, involves a lower daily dose of oral antifungal medication for at least one year. This prevents the infection from coming back while the immune system rebuilds, particularly in people starting or restarting HIV treatment.
Managing Pressure in the Brain
Elevated pressure inside the skull is one of the most dangerous complications and a major driver of poor outcomes. Treatment guidelines recommend aggressive management with repeated spinal taps to drain excess fluid. The goal is to bring the pressure down to a safe level, typically performed daily until readings stabilize.
In some cases, when pressure remains dangerously high despite repeated drainage, a surgical shunt may be placed to continuously divert fluid from the brain to the abdomen. Studies in critically ill patients have shown that those who receive a shunt tend to survive longer than those managed without one, though the procedure carries its own risks, including infection at the surgical site.
The Challenge of Immune Recovery
For people with HIV, starting antiretroviral therapy (ART) is essential for long-term survival, but the timing is tricky. When the immune system begins recovering after starting ART, it can mount an intense inflammatory response against the fungus still present in the body. This reaction, called immune reconstitution inflammatory syndrome (IRIS), can actually make symptoms worse, sometimes dramatically.
IRIS can show up in two ways: a flare-up of already-diagnosed cryptococcal meningitis, or the sudden appearance of symptoms in someone who had an undetected infection. To reduce this risk, current guidelines recommend delaying ART for at least two weeks after beginning antifungal treatment for cryptococcal infection. For meningitis specifically, the delay is often longer, with the exact timing guided by clinical judgment.
Long-Term Outlook
Without treatment, cryptococcal meningitis is almost always fatal. Even with treatment, mortality remains high, particularly in low-resource settings where it reaches roughly 70%. In well-equipped hospitals with access to the full range of antifungal medications and close monitoring, survival rates improve significantly, but the disease still carries serious risks.
Survivors often face lasting neurological effects. Vision problems, hearing loss, chronic headaches, difficulty with coordination, and cognitive changes are all possible long-term consequences, particularly if elevated brain pressure wasn’t controlled quickly. The severity of these outcomes depends heavily on how early treatment began and how effectively the pressure was managed during the acute illness.
For people living with HIV, sustained viral suppression through ART and immune recovery are the strongest protections against relapse. The maintenance phase of antifungal therapy can be stopped after at least a year, provided the immune system has recovered sufficiently and the infection remains under control.